Yong Liang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11952007/publications.pdf

Version: 2024-02-01

		623734	752698
19	1,523	14	20
papers	citations	h-index	g-index
20	20	20	3182
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity. Journal of Clinical Investigation, 2022, 132, .	8.2	38
2	DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. Cancer Cell, 2021, 39, 96-108.e6.	16.8	153
3	Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity. Clinical Cancer Research, 2021, 27, 3818-3824.	7.0	21
4	Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity. Cell Research, 2021, 31, 1190-1198.	12.0	34
5	Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance. Nature Communications, 2021, 12, 5866.	12.8	39
6	PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nature Communications, 2020, 11, 4835.	12.8	290
7	Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3–CD8+ T cells. JCI Insight, 2020, 5, .	5.0	30
8	A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control. Nature Communications, 2019, 10, 3874.	12.8	132
9	T cell-derived lymphotoxin limits Th1 response during HSV-1 infection. Scientific Reports, 2018, 8, 17727.	3.3	7
10	Targeting IFN $\hat{l}\pm$ to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance. Nature Communications, 2018, 9, 4586.	12.8	60
11	PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression. Journal of Clinical Investigation, 2018, 128, 580-588.	8.2	388
12	T Cell-Derived Lymphotoxin Is Essential for the Anti-Herpes Simplex Virus 1 Humoral Immune Response. Journal of Virology, 2018, 92, .	3.4	7
13	CTLA-4 Limits Anti-CD20–Mediated Tumor Regression. Clinical Cancer Research, 2017, 23, 193-203.	7.0	35
14	Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse. Science Translational Medicine, 2016, 8, 333ra47.	12.4	83
15	STING-cytosolic DNA sensing: the backbone for an effective tumor radiation therapy. Annals of Translational Medicine, 2016, 4, 60.	1.7	13
16	Innate lymphotoxin receptor mediated signaling promotes HSV-1 associated neuroinflammation and viral replication. Scientific Reports, 2015, 5, 10406.	3.3	8
17	Deficiency of CD40 Reveals an Important Role for LIGHT in Anti-Leishmanialmmunity. Journal of Immunology, 2015, 195, 194-202.	0.8	11
18	Innate Lymphoid Cells Control Early Colonization Resistance against Intestinal Pathogens through ID2-Dependent Regulation of the Microbiota. Immunity, 2015, 42, 731-743.	14.3	102

#	Article	IF	CITATIONS
19	A Dendritic-Cell-Stromal Axis Maintains Immune Responses in Lymph Nodes. Immunity, 2015, 42, 719-730.	14.3	69